The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor iipositive breast cancer treated with adjuvant trastuzumab therapy

Download
  1. Get@NRC: The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor iipositive breast cancer treated with adjuvant trastuzumab therapy (Opens in a new window)
DOIResolve DOI: http://doi.org/10.1016/j.jacc.2010.11.063
AuthorSearch for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for:
TypeArticle
Journal titleJournal of the American College of Cardiology
ISSN0735-1097
Volume57
Issue22
Pages22632270; # of pages: 8
Subjectbeta adrenergic receptor blocking agent; brain natriuretic peptide; C reactive protein; cyclophosphamide; dipeptidyl carboxypeptidase inhibitor; doxorubicin; epidermal growth factor receptor 2; fluorouracil; trastuzumab; troponin T; adult; article; breast cancer; cancer adjuvant therapy; cardiomyopathy; cardiotoxicity; cardiovascular magnetic resonance; clinical article; controlled study; diagnostic imaging; drug efficacy; drug safety; drug withdrawal; female; heart failure; heart left ventricle ejection fraction; heart left ventricle endsystolic volume; heart left ventricle failure; human; priority journal; prospective study; sensitivity and specificity; transthoracic echocardiography; treatment duration; treatment response; Adult; Antibodies, Monoclonal; Biological Markers; Breast Neoplasms; C-Reactive Protein; Echocardiography, Doppler; Female; Heart; Humans; Magnetic Resonance Imaging, Cine; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Receptor, erbB-2; Risk Assessment; Sensitivity and Specificity; Troponin T; Ventricular Dysfunction, Left
AbstractObjectives: The aim of this study was to evaluate whether cardiac biomarkers, tissue velocity (TVI) and strain imaging, and cardiac magnetic resonance imaging can predict early left ventricular (LV) dysfunction in human epidermal growth factor receptor IIpositive breast cancer patients treated with trastuzumab in the adjuvant setting. Background: Early indexes of LV systolic dysfunction with noninvasive cardiac imaging would be useful for addressing the cardiac safety profile of trastuzumab, potentially avoiding the detrimental effects of heart failure. Methods: We used cardiac biomarkers, TVI and strain imaging, and cardiac magnetic resonance imaging to detect pre-clinical changes in LV systolic function, before conventional changes in left ventricular ejection fraction (LVEF) in human epidermal growth factor receptor IIpositive breast cancer patients treated with trastuzumab in the adjuvant setting. Results: Of 42 patients (mean age 47 ± 9 years) prospectively followed between 2007 and 2009, 10 (25%) developed trastuzumab-mediated cardiomyopathy (CM). Troponin T, C-reactive protein, and brain natriuretic peptide did not change over time. Within 3 months of adjuvant therapy with trastuzumab, there was a significant difference in the lateral S′ between the normal cohort and the CM group (9.1 ± 1.6 cm/s and 6.4 ± 0.6 cm/s, respectively, p < 0.05). Similarly, the peak global longitudinal and radial strain decreased as early as 3 months in the trastuzumab-mediated cardiotoxicity group. As compared with both global longitudinal and radial strain, only S′ was able to identify all 10 patients who developed trastuzumab-mediated CM. The LVEF subsequently decreased at 6 months of follow-up in all 10 patients, necessitating discontinuation of the drug. All 10 patients demonstrated delayed enhancement of the lateral wall of the LV within the mid-myocardial portion, consistent with trastuzumab-induced CM. Conclusions: Both TVI and strain imaging were able to detect pre-clinical changes in LV systolic function, before conventional changes in LVEF, in patients receiving trastuzumab in the adjuvant setting. © 2011 American College of Cardiology Foundation.
Publication date
LanguageEnglish
AffiliationNational Research Council Canada (NRC-CNRC)
Peer reviewedYes
NPARC number21271705
Export citationExport as RIS
Report a correctionReport a correction
Record identifier5452ae00-c8fb-4e0b-a2a8-ee9a94bffe27
Record created2014-03-24
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)